Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer

Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer

The data presented herein are supplementary to our published primary article “A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer”[1]. The exploratory analysis evaluated the impac...

Full description

Bibliographic Details
Main Authors: Bradley J. Monk, Thomas J. Herzog, George Wang, Spyros Triantos, Scott Maul, Roland Knoblauch, Tracy McGowan, Waleed S.W. Shalaby, Robert L. Coleman
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Data in Brief
Subjects:
Overall survival
Pegylated liposomal doxorubicin
Trabectedin
Recurrent ovarian cancer
Response rate
Online Access:http://www.sciencedirect.com/science/article/pii/S2352340920303590

Internet

http://www.sciencedirect.com/science/article/pii/S2352340920303590

Similar Items